Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.

@article{Chuang2014EzetimibeMA,
  title={Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.},
  author={Jen-Chieh Chuang and Adam M. Lopez and Kenneth S. Posey and Stephen D. Turley},
  journal={Biochemical and biophysical research communications},
  year={2014},
  volume={443 3},
  pages={1073-7}
}
Lysosomal acid lipase (LAL) plays a critical role in the intracellular handling of lipids by hydrolyzing cholesteryl esters (CE) and triacylglycerols (TAG) contained in newly internalized lipoproteins. In humans, mutations in the LAL gene result in cholesteryl ester storage disease (CESD), or in Wolman disease (WD) when the mutations cause complete loss of… CONTINUE READING